IFNG and B-cell chronic lymphocytic leukemia: The immunogenicity endpoint was not reached: CLL-specific induced IFN-γ T cell responses to at least one peptide were documented only in 19.2% (5/26) of all study patients (within MRD-negative arm 16.7% (2/12), MRD positive without lenalidomide 16.7% (2/12), and MRD positive with lenalidomide 50% (1/2)) until end of study (Figure 5; Supplementary Figure S2).